Skip to main
SXTP

SXTP Stock Forecast & Price Target

SXTP Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

60 Degrees Pharmaceuticals Inc has demonstrated significant financial growth, with net product revenues soaring by 140% to $607.6k in FY24, and a remarkable 223% year-over-year increase in Q3 FY25, highlighting strong demand for ARAKODA. The continuing sales increase in ARAKODA, which has shown consistent year-over-year growth, positions the company favorably within the specialty pharmaceutical market, reinforcing its potential for sustainable revenue generation. Additionally, the broadening application of Tafenoquine due to its favorable safety profile, combined with rising incidences of diseases like babesiosis, suggests increasing market potential for the company's pipeline products, promising further opportunities for future growth and commercialization.

Bears say

60 Degrees Pharmaceuticals Inc faces a negative outlook primarily due to depressed forward multiples resulting from current market volatility and financial instability characterized by a reported gross loss of approximately $9,000 for Q3 FY24, attributed to a one-time inventory write-off. The company also grapples with low visibility on regulatory approvals for its new indications, posing significant risks of potential dilution from financing options. Additionally, concerns over commercial viability arise from diminishing demand and increased competition in its therapeutic areas, exacerbated by emerging resistance to current treatment strategies and associated tolerability issues that could hinder patient compliance.

SXTP has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 60 Degrees Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 60 Degrees Pharmaceuticals Inc (SXTP) Forecast

Analysts have given SXTP a Strong Buy based on their latest research and market trends.

According to 2 analysts, SXTP has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

60 Degrees Pharmaceuticals Inc (SXTP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.